Bone Marrow Aspiration and Biopsy Medical Services in China

Bone marrow aspiration and biopsy is a diagnostic medical procedure—not a disease—commonly performed in the Department of Hematology to evaluate hematopoietic function, detect blood disorders, and assess bone marrow involvement in systemic conditions. It involves two complementary techniques: aspiration (withdrawal of liquid marrow using a needle) and biopsy (removal of a small core of solid marrow tissue), typically conducted from the posterior iliac crest under local anesthesia. The procedure is essential for diagnosing and staging hematologic malignancies—including leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes—as well as evaluating unexplained cytopenias (anemia, neutropenia, thrombocytopenia), pancytopenia, suspected metastatic cancer, storage disorders (e.g., Gaucher disease), and infections such as tuberculosis or fungal myelitis. Pathogenesis relevance lies not in the procedure itself but in its role to uncover underlying pathophysiologic mechanisms—such as clonal hematopoiesis, marrow infiltration, fibrosis, dysplasia, or hypocellularity—that drive clinical hematologic dysfunction. Epidemiologically, the procedure is routinely indicated across all age groups but most frequently in adults aged 50–75 years, reflecting the higher incidence of hematologic cancers and age-related marrow changes. In China, over 200,000 bone marrow examinations are performed annually in tertiary hospitals, with rising demand driven by improved diagnostics, aging population, and expanded screening for early hematologic neoplasms. Key risk factors prompting referral include persistent fatigue, recurrent infections, unexplained bruising or bleeding, night sweats, weight loss, lymphadenopathy, hepatosplenomegaly, and abnormal peripheral blood counts on routine CBC. While the procedure itself carries low morbidity—minor pain, transient bleeding, or localized infection in <2% of cases—the psychological burden, procedural anxiety, and delays in definitive diagnosis can significantly impair quality of life. Patients often experience anticipatory distress, fear of malignancy, and disruption in daily functioning during the diagnostic odyssey; those with chronic hematologic conditions may face repeated aspirations over time, compounding emotional and physical strain. Importantly, timely and accurate bone marrow evaluation directly informs prognosis, therapeutic selection (e.g., chemotherapy vs. targeted therapy vs. transplant), and monitoring response—making it a cornerstone of precision hematology care.

Bone marrow aspiration and biopsy (BMAB) are diagnostic and monitoring procedures—not diseases—performed primarily in hematology to evaluate hematopoietic function, detect malignancies, assess marrow architecture, and investigate cytopenias or unexplained systemic symptoms. The decision to perform BMAB is driven by clinical indications rather than causation; however, understanding the underlying pathologies prompting the procedure informs risk stratification and procedural planning. Common clinical indications (often termed 'causes' in a broad sense) include suspected hematologic malignancies such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma, and lymphomas with marrow involvement. Non-malignant indications encompass unexplained cytopenias (anemia, neutropenia, thrombocytopenia), pancytopenia, suspected marrow infiltration (e.g., by granulomatous disease, metastatic carcinoma, or storage disorders), evaluation of iron stores and dyserythropoiesis, staging of systemic diseases (e.g., sarcoidosis, amyloidosis), and assessment of treatment response or residual disease post-chemotherapy or stem cell transplantation. Triggers for urgent BMAB include rapidly progressive cytopenias, circulating blasts on peripheral smear, febrile neutropenia with unclear etiology, or suspicion of acute leukemia based on clinical and laboratory findings (e.g., elevated LDH, hyperuricemia, coagulopathy). Risk factors influencing procedural safety and diagnostic yield include patient-specific comorbidities: severe thrombocytopenia (<50 × 10⁹/L) increases bleeding risk; uncontrolled anticoagulation or antiplatelet therapy (e.g., warfarin, direct oral anticoagulants, clopidogrel) necessitates careful peri-procedural management; advanced age (>75 years) correlates with increased procedural discomfort and higher likelihood of inadequate samples due to marrow fibrosis or osteosclerosis. Anatomical challenges—such as prior pelvic radiation, severe osteoporosis, or skeletal deformities (e.g., ankylosing spondylitis)—may compromise site accessibility and sample adequacy. Genetic factors indirectly influence BMAB necessity and interpretation: germline mutations in genes such as RUNX1, GATA2, ETV6, or DDX41 predispose to familial MDS/AML and warrant earlier or more frequent marrow surveillance. Constitutional bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) involve telomere biology defects and carry high risks of clonal evolution, mandating vigilant marrow monitoring. Inherited thrombocytopenias (e.g., MYH9-related disorders) may complicate bleeding risk assessment pre-procedure. Environmental exposures significantly contribute to conditions prompting BMAB: prolonged occupational exposure to benzene, ionizing radiation, or chemotherapeutic alkylating agents increases risk of therapy-related MDS/AML. Chronic viral infections—including HIV, hepatitis C, and Epstein-Barr virus—can induce marrow suppression or lymphoproliferative disorders requiring histopathologic confirmation. Autoimmune conditions (e.g., systemic lupus erythematosus) may cause immune-mediated cytopenias or marrow hypocellularity, necessitating biopsy to exclude alternative diagnoses. Nutritional deficiencies (e.g., severe vitamin B12 or folate deficiency) can mimic MDS morphologically, underscoring the need for concurrent metabolic testing alongside BMAB. Geographic and socioeconomic factors also modulate risk: endemic regions for visceral leishmaniasis (kala-azar) or tuberculosis may present with pancytopenia and require marrow examination for pathogen identification. Finally, iatrogenic triggers—including immunosuppressive regimens (e.g., alemtuzumab, fludarabine) or checkpoint inhibitors—can induce immune-mediated marrow injury or clonal hematopoiesis, prompting diagnostic BMAB. While BMAB itself carries low procedural morbidity (bleeding, infection, transient pain), its utility hinges on accurate pre-test probability assessment, integration of genetic and environmental context, and multidisciplinary interpretation of morphology, flow cytometry, cytogenetics, and molecular studies. Thus, the 'causes' for performing BMAB reflect a complex interplay of acquired pathology, inherited susceptibility, environmental insult, and therapeutic exposure—all evaluated within the framework of evidence-based hematology practice.

Bone marrow aspiration and biopsy are diagnostic procedures—not diseases—and therefore do not produce intrinsic symptoms. However, patients undergoing these procedures—typically referred from hematology for evaluation of suspected hematologic malignancies, cytopenias, unexplained cytosis, storage disorders, or systemic infections—often present with a constellation of clinical manifestations reflective of the underlying pathology. Understanding the symptom profile is essential for appropriate patient selection, procedural counseling, and interpretation of findings.

Early symptoms prompting referral for bone marrow evaluation are frequently nonspecific and insidious. Fatigue, pallor, and exertional dyspnea commonly reflect anemia—often normocytic or macrocytic—and may precede overt laboratory abnormalities by weeks to months. Unexplained bruising (ecchymoses), petechiae, or prolonged bleeding after minor trauma suggest thrombocytopenia or platelet dysfunction. Recurrent or atypical infections—such as sinusitis, pneumonia, or cellulitis with poor response to standard antibiotics—may indicate neutropenia or functional leukocyte defects. Low-grade fevers without localizing signs, night sweats, and unintentional weight loss (>10% body weight over 6 months) constitute B-symptoms, highly suggestive of lymphoproliferative disorders (e.g., lymphoma, chronic lymphocytic leukemia) or myeloid neoplasms (e.g., chronic myelomonocytic leukemia). Early constitutional symptoms may also include pruritus (especially in polycythemia vera or lymphoma), early satiety or left upper quadrant discomfort (due to splenomegaly in myeloproliferative neoplasms or infiltrative disorders), or bone pain localized to the sternum, pelvis, or vertebrae—particularly if persistent, nocturnal, or unrelieved by rest—raising concern for marrow infiltration (e.g., multiple myeloma, metastatic carcinoma, or acute leukemia).

Typical symptoms at the time of diagnosis often reflect progressive marrow failure or organ infiltration. Pancytopenia manifests as concurrent anemia (fatigue, tachycardia, lightheadedness), thrombocytopenia (mucocutaneous bleeding, menorrhagia, retinal hemorrhages), and neutropenia (fever, oral ulcers, bacterial sepsis). In acute leukemias, patients may present with leukostasis-related symptoms—including headache, visual changes, confusion, or respiratory distress—when white blood cell counts exceed 100 × 10⁹/L. Hypercalcemia (from osteoclast activation in myeloma or lymphoma) causes polyuria, polydipsia, constipation, confusion, and ECG changes (prolonged QT interval). Hyperviscosity syndrome (in Waldenström macroglobulinemia or high-burden plasma cell disorders) produces blurred vision, headache, vertigo, and mucosal bleeding. Bone pain—especially axial skeletal pain worsening with movement or lying supine—is classic in multiple myeloma and metastatic disease; lytic lesions may precipitate pathologic fractures. Hepatosplenomegaly or lymphadenopathy may be palpable on physical exam and correlates with marrow involvement in lymphoid or myeloid malignancies.

Accompanying symptoms provide critical diagnostic context. Pruritus after hot showers (aquagenic pruritus) strongly supports polycythemia vera. Gouty arthritis or renal stones suggest chronic hyperuricemia in proliferative disorders. Skin manifestations—including xanthomas (hyperlipidemia in monoclonal gammopathy), purpura (amyloidosis), or violaceous papules (leukemia cutis)—are red-flag signs. Neurologic symptoms such as peripheral neuropathy (e.g., IgM paraprotein in Waldenström), spinal cord compression (epidural plasmacytoma), or cranial nerve palsies (lymphomatous meningitis) indicate advanced or extramedullary disease. Laboratory accompaniments include elevated lactate dehydrogenase (LDH), uric acid, or serum free light chains; abnormal serum protein electrophoresis (SPEP) or immunofixation; and circulating blasts or atypical lymphocytes on peripheral smear.

Complications related to the underlying disease—not the procedure itself—dominate clinical concern. Marrow failure increases risk of life-threatening infection, hemorrhage, and cardiac decompensation. Leukemic infiltration can cause spinal cord compression, superior vena cava syndrome, or tumor lysis syndrome (characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, and acute kidney injury). Amyloid deposition leads to restrictive cardiomyopathy, nephrotic syndrome, or autonomic neuropathy. Myelofibrosis results in extramedullary hematopoiesis with massive splenomegaly, portal hypertension, and cachexia. Rarely, aggressive lymphomas or leukemias cause hemophagocytic lymphohistiocytosis (HLH), presenting with cytopenias, fever, hepatosplenomegaly, and hyperferritinemia.

Diagnosis relies on integration of clinical assessment, peripheral blood examination, imaging, and bone marrow evaluation. Peripheral blood smear remains the initial cornerstone: it identifies blast percentage, dysplastic features (e.g., pseudo-Pelger-Huët, ring sideroblasts), abnormal granulation, or atypical lymphocytes. Flow cytometry detects aberrant antigen expression in hematologic malignancies. Cytogenetic analysis (karyotyping) and molecular testing (e.g., JAK2 V617F, CALR, MPL, BCR-ABL1, FLT3-ITD, NPM1) are performed on aspirate or biopsy tissue. The bone marrow aspirate provides cellular morphology and cytochemistry (e.g., myeloperoxidase, periodic acid–Schiff); the trephine biopsy assesses architecture, cellularity, fibrosis (reticulin staining), and spatial distribution of infiltrates. Imaging—including PET-CT for lymphoma staging or MRI for vertebral involvement in myeloma—is complementary. Serum and urine studies (e.g., SPEP, UPEP, free light chains, β₂-microglobulin) quantify monoclonal proteins and assess tumor burden.

Differential diagnosis must systematically exclude reactive and malignant etiologies. Cytopenias require distinction between nutritional deficiencies (B12/folate deficiency—macrocytosis, hypersegmented neutrophils), autoimmune disorders (immune-mediated cytopenias with positive Coombs or ANA), viral suppression (EBV, HIV, parvovirus B19), drug-induced marrow toxicity (chemotherapy, antibiotics, antithyroid agents), and hypersplenism. Unexplained cytosis mandates evaluation for secondary causes (hypoxia, smoking, renal tumors) versus clonal myeloproliferative neoplasms. Bone pain necessitates differentiation between primary marrow disorders (myeloma, leukemia), metastatic solid tumors (breast, prostate, lung), metabolic bone disease (osteoporosis, Paget disease), or inflammatory arthropathies. Lymphadenopathy and B-symptoms require exclusion of infectious mononucleosis, tuberculosis, sarcoidosis, and autoimmune lymphoproliferative syndrome before diagnosing lymphoma or CLL. Finally, marrow fibrosis must be distinguished between primary myelofibrosis and secondary causes including metastatic carcinoma, lymphoma, tuberculosis, or chronic inflammatory states. Accurate diagnosis hinges on correlating morphologic, immunophenotypic, cytogenetic, and clinical data per WHO and ICC classification frameworks.

Bone marrow aspiration and biopsy (BMAB) is a cornerstone diagnostic and staging procedure in hematology, primarily performed to evaluate hematologic malignancies (e.g., acute and chronic leukemias, lymphomas, multiple myeloma), bone marrow failure syndromes (e.g., aplastic anemia, myelodysplastic syndromes), unexplained cytopenias or cytoses, suspected metastatic disease, storage disorders, and infections such as disseminated tuberculosis or histoplasmosis. It is not a therapeutic intervention per se but serves as the critical gateway to accurate diagnosis, risk stratification, treatment selection, and response monitoring. As such, its clinical utility lies in guiding subsequent conservative, pharmacologic, or surgical interventions.

Conservative management refers to non-invasive, supportive, or observation-based strategies employed before, after, or instead of BMAB—depending on clinical context. In patients with mild, stable cytopenias and low suspicion for malignancy, watchful waiting with serial peripheral blood counts and clinical assessment may be appropriate. For those with iron deficiency anemia or vitamin B12/folate deficiency, conservative correction via oral supplementation and dietary counseling obviates the need for BMAB. Similarly, in cases of reactive thrombocytosis or leukocytosis secondary to infection or inflammation, treating the underlying cause—without bone marrow evaluation—is standard. Conservative measures also include transfusion support (packed red blood cells for symptomatic anemia; platelet transfusions for severe thrombocytopenia with bleeding risk), growth factor administration (e.g., erythropoietin for anemia in chronic kidney disease; granulocyte colony-stimulating factor for neutropenia), and infection prophylaxis in immunocompromised patients. These approaches aim to stabilize the patient while diagnostic clarity is pursued.

Medication plays a pivotal role both pre- and post-procedure and, more importantly, as definitive therapy following BMAB-derived diagnoses. Prophylactic antibiotics are generally unnecessary for routine BMAB in immunocompetent patients but may be indicated in neutropenic or immunosuppressed individuals. Analgesics—including acetaminophen or short-term NSAIDs—are routinely administered for localized post-procedural discomfort; opioids are rarely required. Anticoagulant or antiplatelet agents (e.g., warfarin, apixaban, clopidogrel) must be carefully reviewed and often temporarily withheld per institutional protocols to minimize bleeding risk, with bridging strategies considered when clinically warranted. Crucially, BMAB results directly inform pharmacotherapy: acute myeloid leukemia (AML) dictates induction chemotherapy (e.g., cytarabine + idarubicin); chronic myeloid leukemia (CML) mandates tyrosine kinase inhibitors (e.g., imatinib, dasatinib); multiple myeloma guides triplet regimens (e.g., lenalidomide–bortezomib–dexamethasone); and autoimmune cytopenias may require corticosteroids, rituximab, or thrombopoietin receptor agonists. Molecular and cytogenetic findings from the aspirate and biopsy (e.g., FLT3, NPM1, BCR-ABL1, del(5q)) further refine targeted therapy selection and prognostication.

Surgical treatment is not applicable to BMAB itself, as it is a minimally invasive outpatient procedure typically performed under local anesthesia at the posterior iliac crest. However, BMAB frequently informs decisions regarding definitive surgical or procedural interventions. For example, confirmation of lymphoma involvement in marrow may prompt referral for radiation oncology or surgical resection of bulky disease. In patients with high-risk MDS or AML, BMAB is mandatory prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT)—a potentially curative but intensive procedure requiring rigorous donor matching, conditioning regimens, and post-transplant immunosuppression. Additionally, BMAB is essential for evaluating engraftment and detecting minimal residual disease (MRD) post-transplant. Rarely, surgical bone biopsy (e.g., from vertebral body or sternum) may be considered if iliac sampling is inadequate or contraindicated—but this is exceptional and carries higher morbidity.

China offers distinct advantages in the execution and integration of BMAB within comprehensive hematologic care. First, major academic centers—including Peking University People’s Hospital, Shanghai Ruijin Hospital, and Guangzhou Institute of Hematology—maintain standardized, evidence-based BMAB protocols aligned with international guidelines (e.g., EHA, ASH), yet optimized for regional epidemiology (e.g., higher incidence of T-cell lymphomas and EBV-associated HLH). Second, China leads in rapid turnaround times: flow cytometry, cytogenetics, and next-generation sequencing (NGS) panels are routinely completed within 3–5 working days, enabling timely therapeutic decisions. Third, cost-effectiveness is notable—BMAB with ancillary studies costs approximately 30–50% less than in Western countries without compromising quality, facilitated by centralized laboratory networks and government-subsidized diagnostics. Fourth, integration with traditional Chinese medicine (TCM) is unique: many centers offer adjunctive TCM formulations (e.g., Bushen Huoxue decoctions) during recovery to ameliorate fatigue and improve hematopoietic recovery—though these are used as supportive, not替代, therapies and are evidence-informed where possible. Finally, China’s robust digital health infrastructure enables seamless longitudinal tracking of BMAB results alongside electronic health records, facilitating AI-assisted morphologic review and predictive analytics for treatment response.

Recovery following BMAB is typically rapid and uncomplicated. Patients are advised to apply firm pressure to the puncture site for 5–10 minutes immediately post-procedure, followed by a sterile dressing. Mild soreness, bruising, or a small hematoma at the site is expected and usually resolves within 3–5 days; acetaminophen is preferred over NSAIDs for analgesia to avoid platelet inhibition. Patients should avoid heavy lifting (>10 lbs), vigorous exercise, or soaking (e.g., baths, swimming) for 48–72 hours to prevent bleeding or infection. Signs requiring urgent evaluation include persistent or worsening pain beyond 72 hours, fever >38.0°C, expanding hematoma, purulent discharge, or new-onset neurologic symptoms (e.g., radicular pain—rare but concerning for nerve injury). Most patients resume normal activities within 24–48 hours. Importantly, psychological recovery matters: anxiety surrounding BMAB is common, particularly among newly diagnosed patients; therefore, clear pre-procedural counseling, real-time communication of preliminary findings (e.g., morphology report within 24 hours), and timely multidisciplinary follow-up (hematologist, oncology nurse, psychosocial support) significantly improve adherence and outcomes. Nutritional support—including adequate protein, iron, folate, and vitamin B12 intake—is encouraged to optimize marrow reserve, especially in patients with underlying nutritional deficiencies or undergoing cytotoxic therapy. Follow-up BMAB may be scheduled at defined intervals (e.g., day 14 post-induction in AML) to assess treatment response, always guided by disease-specific consensus criteria (e.g., ELN 2022 for AML, IMWG for myeloma). Ultimately, BMAB remains indispensable—not as an endpoint, but as the foundational step that transforms uncertainty into precision hematology.